NCT03860207 2023-09-13Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor CancersY-mAbs TherapeuticsPhase 1/2 Terminated12 enrolled 15 charts